10x Genomics (TXG)

• Market cap: $1.83B
• 1 day: -0.07%
• 5 days: -8.05%
• 1 month: 2.45%
• 3 months: 1.48%
• 6 months: -23.99%
• Year to date: 6.27%
• 1 year: -64.01%
• 5 years: -81.97%
• 10 years: -71.41%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Employees: 1,259

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

209% more call options, than puts

Call options by funds: $6.36M | Put options by funds: $2.06M

39% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 72

18% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 49

9% more capital invested

Capital invested by funds: $2.16B [Q2] → $2.36B (+$200M) [Q3]

2% more funds holding

Funds holding: 257 [Q2] → 261 (+4) [Q3]

6.89% less ownership

Funds ownership: 105.27% [Q2] → 98.37% (-6.89%) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 2 (-2) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 7% downside
• Avg. target: $19.67 30% upside
• High target: $28 86% upside

6 analyst ratings

• positive: 3 50%
• neutral: 2 33%
• negative: 1 17%

Morgan Stanley Tejas Savant 29% 1-year accuracy 4 / 14 met price target	86% upside $28	Overweight Maintained	13 Jan 2025
Barclays Luke Sergott 23% 1-year accuracy 11 / 48 met price target	26% upside $19	Overweight Maintained	1 Nov 2024
Citigroup Patrick Donnelly 47% 1-year accuracy 15 / 32 met price target	53% upside $23	Buy Maintained	30 Oct 2024
Goldman Sachs Matthew Sykes 60% 1-year accuracy 25 / 42 met price target	7% downside $14	Sell Maintained	30 Oct 2024
JP Morgan Rachel Vatnsdal 47% 1-year accuracy 8 / 17 met price target	7% downside $14	Neutral Maintained	30 Oct 2024